Update shared on08 Aug 2025
Fair value Increased 11%Ligand Pharmaceuticals’ consensus price target has increased to $154.75, primarily driven by a notable surge in net profit margin and a sharp reduction in future P/E, indicating improved profitability and valuation.
What's in the News
- Ligand Pharmaceuticals raised 2025 revenue guidance to $200–225 million from $180–200 million.
- Partner Pelthos Therapeutics commercially launched ZELSUVMI (berdazimer) topical gel 10.3%, with Ligand receiving a $5 million milestone payment; following the Pelthos merger with Channel Therapeutics, Ligand now owns 56% of Pelthos and is entitled to a 13% royalty on worldwide sales of ZELSUVMI plus potential additional milestones.
- Ligand Pharmaceuticals was added to multiple Russell growth and small cap benchmarks and indexes, including the Russell 2000, 2500, 3000, 3000E, Small Cap Comp, and their respective growth subindexes.
Valuation Changes
Summary of Valuation Changes for Ligand Pharmaceuticals
- The Consensus Analyst Price Target has risen from $146.00 to $154.75.
- The Net Profit Margin for Ligand Pharmaceuticals has significantly risen from 38.28% to 72.57%.
- The Future P/E for Ligand Pharmaceuticals has significantly fallen from 35.86x to 18.29x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.